Yuanli Zhen

Yuanli Zhen

Auto-generated profile, based on publicly available information

Yuanli Zhen

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QWQibiao Wu
Qibiao Wu
HEHaley Ellis
Haley Ellis
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
AMAlexa G. Michel
Alexa G. Michel
BNBryanna L. Norden
Bryanna L. Norden
NBNabeel Bardeesy
Nabeel Bardeesy
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible inhibitor, futibatinib. However, acquired resistance develops, limiting clinical benefit. Some mechanisms of resistance have been reported, including secondary FGFR2 kinase domain mutations. Here, we sought to establish the landscape of acquired resistance to FGFR inhibition and to validate findings in model systems. Experimental Design: We examined the spectrum of acquired resistance mechanisms detected in circulating tumor DNA or tumor tissue upon disease progression following FGFR inhibitor therapy in 82 FGFR2-altered cholangiocarcinoma patients from 12 published reports. Functional studies of candidate resistance alterations were performed. Results: Overall, 49 of 82 patients (60%) had one or more detectable secondary FGFR2 kinase domain mutations upon acquired resistance. N550 molecular brake and V565 gatekeeper mutations were most common, representing 63% and 47% of all FGFR2 kinase domain mutations, respectively. Functional studies showed different inhibitors displayed unique activity profiles against FGFR2 mutations. Interestingly, disruption of the cysteine residue covalently bound by futibatinib (FGFR2 C492) was rare, observed in 1 of 42 patients treated with this drug. FGFR2 C492 mutations were insensitive to inhibition by futibatinib but showed reduced signaling activity, potentially explaining their low frequency. Conclusions: These data support secondary FGFR2 kinase domain mutations as the primary mode of acquired resistance to FGFR inhibitors, most commonly N550 and V565 mutations. Thus, development of combination strategies and next-generation FGFR inhibitors targeting the full spectrum of FGFR2 resistance mutations will be critical.

7 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYuanli Zhen
Yuanli Zhen
KLKai Liu
Kai Liu
LSLei Shi
Lei Shi
SSSimran Shah
Simran Shah
QXQin Xu
Qin Xu
NBNabeel Bardeesy
Nabeel Bardeesy
Genomic alterations that activate Fibroblast Growth Factor Receptor 2 (FGFR2) are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to FGFR inhibition. However, the depth and duration of response is often limited. Here, we conduct integrative transcriptomics, metabolomics, and phosphoproteomics analysis of patient-derived models to define pathways downstream of oncogenic FGFR2 signaling that fuel ICC growth and to uncover compensatory mechanisms associated with pathway inhibition. We find that FGFR2-mediated activation of Nuclear factor-κB (NF-κB) maintains a highly glycolytic phenotype. Conversely, FGFR inhibition blocks glucose uptake and glycolysis while inciting adaptive changes, including switching fuel source utilization favoring fatty acid oxidation and increasing mitochondrial fusion and autophagy. Accordingly, FGFR inhibitor efficacy is potentiated by combined mitochondrial targeting, an effect enhanced in xenograft models by intermittent fasting. Thus, we show that oncogenic FGFR2 signaling drives NF-κB-dependent glycolysis in ICC and that metabolic reprogramming in response to FGFR inhibition confers new targetable vulnerabilities.

4 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EBEranga R. Balasooriya
Eranga R. Balasooriya
QWQibiao Wu
Qibiao Wu
HEHaley Ellis
Haley Ellis
YZYuanli Zhen
Yuanli Zhen
BNBryanna L. Norden
Bryanna L. Norden
NBNabeel Bardeesy
Nabeel Bardeesy
Purpose: FGFR2 and FGFR3 show oncogenic activation in many cancer types, often through chromosomal fusion or extracellular domain mutation. FGFR2 and FGFR3 alterations are most prevalent in intrahepatic cholangiocarcinoma (ICC) and bladder cancers, respectively, and multiple selective reversible and covalent pan-FGFR tyrosine kinase inhibitors (TKI) have been approved in these contexts. However, resistance, often due to acquired secondary mutations in the FGFR2/3 kinase domain, limits efficacy. Resistance is typically polyclonal, involving a spectrum of different mutations that most frequently affect the molecular brake and gatekeeper residues (N550 and V565 in FGFR2). Experimental Design: Here, we characterize the activity of the next-generation covalent FGFR inhibitor, KIN-3248, in preclinical models of FGFR2 fusion+ ICC harboring a series of secondary kinase domain mutations, in vitro and in vivo. We also test select FGFR3 alleles in bladder cancer models. Results: KIN-3248 exhibits potent selectivity for FGFR1–3 and retains activity against various FGFR2 kinase domain mutations, in addition to being effective against FGFR3 V555M and N540K mutations. Notably, KIN-3248 activity extends to the FGFR2 V565F gatekeeper mutation, which causes profound resistance to currently approved FGFR inhibitors. Combination treatment with EGFR or MEK inhibitors potentiates KIN-3248 efficacy in vivo, including in models harboring FGFR2 kinase domain mutations. Conclusions: Thus, KIN-3248 is a novel FGFR1–4 inhibitor whose distinct activity profile against FGFR kinase domain mutations highlights its potential for the treatment of ICC and other FGFR-driven cancers.

12 May 2025 in Cancer Discovery
Verified
Journal Article
Closed access
VVVindhya Vijay
Vindhya Vijay
NKNegin Karisani
Negin Karisani
LSLei Shi
Lei Shi
YHYu-Han Hung
Yu-Han Hung
PVPhuong Vu
Phuong Vu
NBNabeel Bardeesy
Nabeel Bardeesy
Biliary tract cancers (BTC) are aggressive malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we report integrative analysis of 63 BTC cell lines via multi-omics and genome-scale CRISPR screens. We identify widespread EGFR dependency in BTC, alongside dependencies selective to anatomic subtypes. Additionally, we delineate strategies to overcome therapeutic resistance, with combined EGFR inhibition potentiating targeting of KRAS-mutant and FGFR2 fusion–driven models and SHP2 inhibition effective in the latter context. Clustering RNA/protein expression and dependencies data revealed functional relationships transcending single-gene alterations, with biliary, squamous, or dual biliary/hepatocyte lineage signatures stratifying BTC models. These subtypes exhibit distinct dependency profiles—including cell fate transcription factors GRHL2, TP63, and HNF1B, respectively—and demonstrate prognostic significance in patient samples. Potential subtype-specific targetable vulnerabilities include integrinα3 and the detoxification enzyme UXS1. This cell line atlas reveals therapeutic targets in molecularly defined BTCs, unveils disease subtypes, and provides a resource for therapeutic development. Significance: This integrative analysis of BTC cell lines defines the landscape of vulnerabilities across BTCs, stratifying distinct subtypes, and provides a key resource for studying disease heterogeneity. The findings highlight strategies for targeting BTCs with specific genomic alterations, as well as broader approaches based on shared molecular programs and essential pathways.

20 January 2026 in Annals of Oncology
Verified
Journal Article
Closed access
HEH. Ellis
H. Ellis
EBE.R. Balasooriya
E.R. Balasooriya
AVA. Varkaris
A. Varkaris
BHB. Hajian
B. Hajian
JWJ. Wan
J. Wan
NBN. Bardeesy
N. Bardeesy

4 September 2025
Verified
Other
Open access
VVVindhya Vijay
Vindhya Vijay
NKNegin Karisani
Negin Karisani
LSLei Shi
Lei Shi
YHYu-Han Hung
Yu-Han Hung
PVPhuong Vu
Phuong Vu
NBNabeel Bardeesy
Nabeel Bardeesy
Excel file containing all data corresponding to Figure 5